Cost-effective aminoglycoside therapy in surgical patients.
There is a risk that the current pressures for hospital cost containment may result in inappropriately restrictive administrative measures. A failure to take into account all factors in estimating the cost of antibiotic therapy yields a greatly distorted view of the importance of acquisition costs. Higher-priced drugs may actually be more cost-effective if they have greater efficacy, wider therapeutic range, and/or are less costly to prepare and administer. Simple microcomputer modeling techniques may be easily employed to examine the economic consequences of therapeutic decisions.
D000583:Amikacin / Q000627:therapeutic use; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004358:Drug Therapy / Q000191:economics*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008962:Models, Theoretical; D011292:Premedication; D012306:Risk; D013530:Surgical Wound Infection / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D000583:Amikacin; D014031:Tobramycin